These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 29571795)

  • 1. Texture analysis of apparent diffusion coefficient maps for treatment response assessment in prostate cancer bone metastases-A pilot study.
    Reischauer C; Patzwahl R; Koh DM; Froehlich JM; Gutzeit A
    Eur J Radiol; 2018 Apr; 101():184-190. PubMed ID: 29571795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps--initial observations.
    Reischauer C; Froehlich JM; Koh DM; Graf N; Padevit C; John H; Binkert CA; Boesiger P; Gutzeit A
    Radiology; 2010 Nov; 257(2):523-31. PubMed ID: 20829534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.
    Perez-Lopez R; Mateo J; Mossop H; Blackledge MD; Collins DJ; Rata M; Morgan VA; Macdonald A; Sandhu S; Lorente D; Rescigno P; Zafeiriou Z; Bianchini D; Porta N; Hall E; Leach MO; de Bono JS; Koh DM; Tunariu N
    Radiology; 2017 Apr; 283(1):168-177. PubMed ID: 27875103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance-guided focused ultrasound for the treatment of painful bone metastases: role of apparent diffusion coefficient (ADC) and dynamic contrast enhanced (DCE) MRI in the assessment of clinical outcome.
    Anzidei M; Napoli A; Sacconi B; Boni F; Noce V; Di Martino M; Saba L; Catalano C
    Radiol Med; 2016 Dec; 121(12):905-915. PubMed ID: 27567615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Prostate Cancer Metastasis by Whole Body Magnetic Resonance Imaging Combined with Bone Scintigraphy and PSA Levels.
    An H; Tao N; Li J; Guan Y; Wang W; Wang Y; Wang F
    Cell Physiol Biochem; 2016; 40(5):1052-1062. PubMed ID: 27941343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pilot study on the detection of antiandrogen resistance using serial diffusion-weighted imaging of bone metastases in prostate cancer.
    Reischauer C; Koh DM; Froehlich JM; Patzwahl R; Binkert CA; Gutzeit A
    J Magn Reson Imaging; 2016 Jun; 43(6):1407-16. PubMed ID: 26587694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diffusion-weighted imaging to evaluate for changes from androgen deprivation therapy in prostate cancer.
    Kim AY; Kim CK; Park SY; Park BK
    AJR Am J Roentgenol; 2014 Dec; 203(6):W645-50. PubMed ID: 25415730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative evaluation of bone metastases from prostate cancer with simultaneous [18F] choline PET/MRI: combined SUV and ADC analysis.
    Wetter A; Lipponer C; Nensa F; Heusch P; Rübben H; Schlosser TW; Pöppel TD; Lauenstein TC; Nagarajah J
    Ann Nucl Med; 2014 Jun; 28(5):405-10. PubMed ID: 24595461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI.
    Eiber M; Holzapfel K; Ganter C; Epple K; Metz S; Geinitz H; Kübler H; Gaa J; Rummeny EJ; Beer AJ
    J Magn Reson Imaging; 2011 May; 33(5):1160-70. PubMed ID: 21509875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-Tumor Quantitative Apparent Diffusion Coefficient Histogram and Texture Analysis to Predict Gleason Score Upgrading in Intermediate-Risk 3 + 4 = 7 Prostate Cancer.
    Rozenberg R; Thornhill RE; Flood TA; Hakim SW; Lim C; Schieda N
    AJR Am J Roentgenol; 2016 Apr; 206(4):775-82. PubMed ID: 27003049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fat Fraction Extracted from Whole-Body Magnetic Resonance (WB-MR) in Bone Metastatic Prostate Cancer: Intra- and Inter-Reader Agreement of Single-Slice and Volumetric Measurements.
    Agazzi GM; Di Meo N; Rondi P; Saeli C; Dalla Volta A; Vezzoli M; Berruti A; Borghesi A; Maroldi R; Ravanelli M; Farina D
    Tomography; 2024 Jun; 10(7):1014-1023. PubMed ID: 39058047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multicompartmental Diffusion Model for Improved Assessment of Whole-Body Diffusion-weighted Imaging Data and Evaluation of Prostate Cancer Bone Metastases.
    Conlin CC; Feng CH; Digma LA; Rodríguez-Soto AE; Kuperman JM; Rakow-Penner R; Karow DS; White NS; Seibert TM; Hahn ME; Dale AM
    Radiol Imaging Cancer; 2023 Jan; 5(1):e210115. PubMed ID: 36705559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body 3D T1-weighted MR imaging in patients with prostate cancer: feasibility and evaluation in screening for metastatic disease.
    Pasoglou V; Michoux N; Peeters F; Larbi A; Tombal B; Selleslagh T; Omoumi P; Vande Berg BC; Lecouvet FE
    Radiology; 2015 Apr; 275(1):155-66. PubMed ID: 25513855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features.
    Perez-Lopez R; Nava Rodrigues D; Figueiredo I; Mateo J; Collins DJ; Koh DM; de Bono JS; Tunariu N
    Invest Radiol; 2018 Feb; 53(2):96-102. PubMed ID: 28906339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
    Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
    Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer?
    Lecouvet FE; El Mouedden J; Collette L; Coche E; Danse E; Jamar F; Machiels JP; Vande Berg B; Omoumi P; Tombal B
    Eur Urol; 2012 Jul; 62(1):68-75. PubMed ID: 22366187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.
    Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H
    AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusion-weighted magnetic resonance imaging in painful bone metastases: Using quantitative apparent diffusion coefficient as an indicator of effectiveness of single fraction versus multiple fraction radiotherapy.
    Musio D; De Francesco I; Galdieri A; Marsecano C; Piciocchi A; Napoli A; De Felice F; Tombolini V
    Eur J Radiol; 2018 Jan; 98():1-6. PubMed ID: 29279145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of diffusion-weighted, intravoxel incoherent motion, and dynamic contrast-enhanced MR imaging in the assessment of response to radiotherapy of lytic bone metastases from breast cancer.
    Gaeta M; Benedetto C; Minutoli F; D'Angelo T; Amato E; Mazziotti S; Racchiusa S; Mormina E; Blandino A; Pergolizzi S
    Acad Radiol; 2014 Oct; 21(10):1286-93. PubMed ID: 25088834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiparametric Magnetic Resonance Imaging of the Prostate: Repeatability of Volume and Apparent Diffusion Coefficient Quantification.
    Fedorov A; Vangel MG; Tempany CM; Fennessy FM
    Invest Radiol; 2017 Sep; 52(9):538-546. PubMed ID: 28463931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.